# Revolade Tablets Specified Drug-use Survey

> **NCT06287268** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **OTHER:** eltrombopag

## Key facts

- **NCT ID:** NCT06287268
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06287268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06287268, "Revolade Tablets Specified Drug-use Survey". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06287268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*